What's Happening?
City Therapeutics, a biotech company recognized as one of BioSpace's NextGen companies for 2026, has successfully raised $99.5 million in a Series B funding round. The funds will be used to further develop its pipeline of RNA interference (RNAi) medicines.
The company's lead asset, CITY-FXI, is currently in Phase 1 development and aims to prevent dangerous blood clots without increasing bleeding risks. Additionally, City Therapeutics is working on treatments for Stargardt disease and other undisclosed targets. The company plans to use the new funding to enhance its next-generation RNAi engineering platform and pursue business development activities. City Therapeutics was co-founded by John Maraganore, former CEO of Alnylam, and is based in Cambridge, Massachusetts.
Why It's Important?
The successful funding round underscores the growing interest and investment in RNAi technology, which holds promise for treating a variety of diseases. City Therapeutics' focus on expanding the application of RNAi beyond traditional targets like the liver could lead to breakthroughs in treating conditions that have been challenging to address with existing therapies. The involvement of prominent investors such as Regeneron Ventures and ARCH Venture Partners highlights the confidence in the company's potential to innovate in the biotech sector. This development could have significant implications for the pharmaceutical industry, potentially leading to new treatment options and advancing the field of precision medicine.
What's Next?
City Therapeutics is expected to continue advancing its RNAi pipeline, with a focus on bringing its lead asset, CITY-FXI, through clinical trials. The company may also explore additional partnerships and collaborations to leverage its RNAi platform for new therapeutic discoveries. As the biotech industry continues to evolve, City Therapeutics' progress could influence future investment trends and research directions in RNAi technology. Stakeholders, including investors and potential partners, will likely monitor the company's developments closely to assess the impact of its innovations on the broader healthcare landscape.
